CELC (Celcuity) ROCE %: -46.79% (As of Mar. 2026)


CELC Celcuity Inc CELC
26 GF Score
Price $107.95
! 2 Warning Signs
View Full Analysis

What is Celcuity ROCE %?

Celcuity CELC +3.22% 26 ROCE % is -46.79% as of Mar. 2026. GuruFocus rates CELC with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Celcuity's annualized ROCE % for the quarter that ended in Mar. 2026 was -46.79%.

Celcuity  (NAS:CELC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Celcuity ROCE % Related Terms

Celcuity ROCE % Historical Data

* Premium members only.

The historical data trend for Celcuity's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity ROCE % Chart

Celcuity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -59.56 -30.34 -33.80 -51.99 -50.30

Celcuity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.86 -102.33 -54.00 -41.70 -46.79
CELC
26GF Score
Celcuity Inc CELC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity ROCE % Calculation

Celcuity's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-159.894/( ( (245.123 - 31.723) + (466.558 - 44.152) )/ 2 )
=-159.894/( (213.4+422.406)/ 2 )
=-159.894/317.903
=-50.30 %

Celcuity's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-187.024/( ( (466.558 - 44.152) + (410.164 - 33.211) )/ 2 )
=-187.024/( ( 422.406 + 376.953 )/ 2 )
=-187.024/399.6795
=-46.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -46.79% mean?
Celcuity (CELC) has a ROCE % of -46.79% as of Mar. 2026.
Is Celcuity's ROCE % too high?
Celcuity's current ROCE % is -46.79%. Overall, Celcuity has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's ROCE % compare to ERAS and TNGX?
Celcuity's ROCE % of -46.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Celcuity's current ROCE % is -46.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (CELC) has a current ROCE % of -46.79%. The current ROCE % is -46.79%. Celcuity's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Celcuity (CELC), the current ROCE % is -46.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges 7VR:Germany
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
26GF Score

Get the complete analysis for CELC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$107.95
Price